Lee Eppstein
Directeur Technique/Scientifique/R&D chez New Brunswick Scientific Co., Inc.
Profil
Lee Eppstein has worked as a Director at Antyra, Inc. and as a Vice President-Technology at New Brunswick Scientific Co., Inc.
Postes actifs de Lee Eppstein
| Sociétés | Poste | Début |
|---|---|---|
New Brunswick Scientific Co., Inc.
 New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Directeur Technique/Scientifique/R&D | 01/02/2000 |
Antyra, Inc.
 Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
New Brunswick Scientific Co., Inc.
New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |
